Data Show Improved Response Rate When Zevalin Plus Rituximab Follows Short Course First-Line Treatment In Patients With Follicular Lymphoma
Biogen Idec (NASDAQ: BIIB) announced today that data presented at the 43rd American Society of Clinical Oncology (ASCO) annual meeting showed that adding Zevalin® (Ibritumomab tiuxetan) radioimmunotherapy to a short course first-line treatment followed by rituximab weekly for four weeks doubled the rate of complete response in patients with follicular lymphoma, from 44 percent with a standard treatment regimen to 88 percent. [click link for full article]
Original post by The Doctor Weighs In
Related Articles
Major Phase III Data Show Zevalin® Significantly Increases Progression Free Survival In Follicular Lymphoma
Major Phase 3 Trial Shows Zevalin® Extends Progression-Free Survival In One Of The Most Common Types Of Lymphoma
Galiximab In Combination With Rituximab In Patients With Previously Untreated Follicular Lymphoma
EU Approval For Zevalin(R) As First-Line Consolidation Treatment
Rituximab Maintenance Therapy Improves Survival In Patients With Relapsed Follicular Lymphoma
Major Phase III Data Show Zevalin® Significantly Increases Progression Free Survival In Follicular Lymphoma
Major Phase 3 Trial Shows Zevalin® Extends Progression-Free Survival In One Of The Most Common Types Of Lymphoma
Galiximab In Combination With Rituximab In Patients With Previously Untreated Follicular Lymphoma
EU Approval For Zevalin(R) As First-Line Consolidation Treatment
Rituximab Maintenance Therapy Improves Survival In Patients With Relapsed Follicular Lymphoma